螞蟻消金再增資45億人幣 上半年賺近4.5億人幣
螞蟻集團旗下、經營「花唄」等業務的重慶螞蟻消費金融,再度增資45億元人民幣(下同),令註冊資本由185億元增至230億元。
螞蟻消金股東之一的舜宇光學(02382.HK)參與今次增資,將按原有股權比例出資2.7億元,繼續持有6%權益,為第三大股東;控股股東螞蟻集團出資22.5億元,保持50%股權。國企重慶渝富成為新投資者,出資近9.3億元,取得4.04%股份。現有股東中,南洋商業銀行及寧德時代(300750.SZ)等未有參與,兩者股權分別攤薄至5.22%及2.78%。
增資公告披露,螞蟻消金今年上半年除稅後淨利潤為4.45億元,而去年全年賺8.41億元。上半年資產淨值187.2億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.